AB 968 amends multiple sections of the Business and Professions Code to make contraceptives — including emergency contraception, over‑the‑counter (OTC) products, and prescription‑only products — an explicit part of existing pharmacy authorities and the licentiate non‑obstruction rule. The bill also clarifies how licentiates may refuse on moral or religious grounds and requires consumer notice about patient rights.
The change centralizes several policy decisions in the California State Board of Pharmacy and the Medical Board of California, while moving day‑to‑day access decisions into pharmacy practice. That combination promises faster access for many patients but also creates new operational, training, and oversight responsibilities for pharmacies and regulators.
At a Glance
What It Does
The bill authorizes pharmacists to furnish emergency contraception, OTC contraceptives, prescription‑only self‑administered hormonal contraceptives, and FDA‑approved nonhormonal contraceptives. Prescription‑only products must be furnished under standardized procedures or protocols approved by the Board of Pharmacy and the Medical Board; OTC contraceptives may be furnished without those statewide protocols. Pharmacists must notify the patient’s primary care provider (or provide a written record if none), provide a standardized factsheet at initiation, and complete a minimum continuing education hour for emergency contraception.
Who It Affects
Retail and clinic pharmacists, pharmacy employers, and their professional associations; the California State Board of Pharmacy and the Medical Board of California, which must develop and enforce protocols; prescribers and primary care providers who will receive furnishing notifications; payers and pharmacy benefits managers who will face 12‑month dispensing requests; and patients seeking contraception, especially in areas with limited clinician access.
Why It Matters
This bill pushes contraceptive access further into the pharmacy channel, reducing the need for a prior clinician visit for many users and creating a state‑level standardization task for two licensing boards. The split between prescription‑only and OTC pathways, plus a 12‑month dispensing option, could change inventory, billing, and care coordination practices across the system.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
AB 968 rewrites several pharmacy‑law provisions to make contraceptives an explicit part of what pharmacists may provide without a prior clinician prescription in the traditional sense. The core operational change is that pharmacists can furnish three categories: emergency contraception drug therapy, OTC contraceptives, and prescription‑only contraceptives — the last category to be furnished only under statewide standardized procedures or protocols developed and approved by the Board of Pharmacy together with the Medical Board of California.
Those protocols must be developed in consultation with clinical stakeholders identified in the bill.
For prescription‑only products the protocols will require use of a self‑screening tool that identifies risk factors consistent with the CDC’s United States Medical Eligibility Criteria for Contraceptive Use (USMEC). The law also authorizes a range of other licensed clinicians to use the same self‑screening approach and to prescribe or furnish contraceptives after appropriate prior examination.
When a pharmacist furnishes a contraceptive, they must either notify the patient’s primary care provider, enter the information into a shared record system as permitted, or give the patient a written record if the patient has no primary care provider.The bill adds a few specific operational duties. Pharmacists furnishing emergency contraception must complete at least one hour of approved continuing education on emergency contraception drug therapy before performing the service.
For each contraceptive initiated under the statute — whether emergency, prescription‑only, hormonal self‑administered, or FDA‑approved nonhormonal — the pharmacist must provide a standardized factsheet that includes indications, contraindications, instructions for use, and follow‑up guidance; the Board will develop that form in consultation with public health and professional bodies. AB 968 also clarifies that pharmacists may dispense up to a 12‑month supply of contraceptives at a patient’s request under the specified conditions, and it preserves the existing professional‑judgment, out‑of‑stock, and conscience‑refusal exceptions while requiring employers to adopt protocols that ensure timely patient access despite an individual licentiate’s objection.Enforcement responsibility for protocol compliance is shared: each licensing board enforces the rules against its licensees.
The bill explicitly states it does not broaden pharmacists’ authority to prescribe medications beyond the contraceptive scope set out in the statute, leaving other prescription authorities unchanged.
The Five Things You Need to Know
The bill requires statewide standardized procedures or protocols (approved by the Board of Pharmacy and the Medical Board) for pharmacists to furnish prescription‑only self‑administered hormonal contraceptives and FDA‑approved nonhormonal contraceptives (Section 4052.3(a)(1)).
Pharmacists may furnish over‑the‑counter contraceptives without those statewide standardized procedures (Section 4052.3(c)).
Before furnishing emergency contraception under the statute a pharmacist must complete at least one hour of approved continuing education on emergency contraception drug therapy (Section 4052.3(b)(2)).
For every contraceptive initiated under the law the pharmacist must provide a board‑developed standardized factsheet covering indications, contraindications, method of use, and need for medical follow‑up (Section 4052.3(d)/(c)).
A pharmacist must dispense, at a patient’s request, up to a 12‑month supply of a contraceptive pursuant to a valid prescription or when furnishing under the statute; however, the pharmacist need not dispense if doing so would violate the licentiate non‑obstruction rules (Section 4064.5(f)).
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Non‑obstruction rule expanded to include contraceptives
Section 733 now says a licentiate (a licensed health professional) must not obstruct a patient’s access to a lawfully prescribed drug or device and expressly applies that rule to emergency contraception, OTC contraceptives, and prescription‑only contraceptives named elsewhere in the bill. The existing exceptions remain: professional judgment where dispensing would violate law or harm the patient, out‑of‑stock handling requirements (notify, transfer, or refer), and a conscience/refusal exception that requires prior written notice to the employer and an employer duty to provide reasonable accommodation and protocols so patient access is preserved. The section also requires consumer notices (per Section 4122) to describe patient rights under this rule, which creates an on‑the‑ground transparency requirement for clinical settings.
Self‑screening tool authorized for contraceptive provision
This amendment permits a wide set of clinicians — including pharmacists acting within the pharmacist’s statutory scope — to use a self‑screening tool to identify patient risk factors and, after an appropriate prior examination, prescribe, furnish, or dispense contraceptives. The statute explicitly allows certain vitals and health history elements (blood pressure, weight, height, and history) to be self‑reported through the tool, which reduces barriers for pharmacist‑led assessment but shifts responsibility onto the tool design and clinician judgment.
Pharmacists’ furnishing authorities and notification duties
Section 4052 adds emergency contraception, OTC, and prescription‑only contraceptives (as defined in Section 4052.3) to the list of items pharmacists may furnish. It also requires pharmacists to notify the patient’s primary care provider or enter the furnishing into a shared patient record system when possible; if a patient lacks a PCP, the pharmacist must provide a written record to the patient. That requirement formalizes a care‑coordination duty on pharmacists and creates an expectation of communication between pharmacies and other clinicians.
Standards, training, factsheets, and enforcement for furnishing contraceptives
This is the operational core: (a) prescription‑only self‑administered hormonal and FDA‑approved nonhormonal contraceptives may be furnished only under standardized procedures or protocols jointly approved by the Board of Pharmacy and the Medical Board, developed in consultation with ACOG, the California Pharmacists Association, and others; (b) emergency contraception may be furnished under either local pharmacist‑prescriber protocols or the statewide protocols; (c) OTC contraceptives do not require those standardized protocols; (d) pharmacists must provide a standardized factsheet at initiation and complete at least one hour of CE on emergency contraception before furnishing it. The section expressly preserves that this furnishing authority does not constitute a general expansion of pharmacists’ prescription authority beyond the contraceptive context and assigns enforcement to each board over its licensees.
12‑month dispensing and supply rules for contraceptives
This amendment carves contraceptives out of the general 90‑day supply rule and creates a specific rule allowing pharmacists to dispense up to a 12‑month supply at a patient’s request, either pursuant to a prescriber’s valid prescription or when the pharmacist furnishes the contraceptive under the statute’s protocols (or for OTC products). The pharmacist must still exercise professional judgment and may not dispense if doing so would violate the non‑obstruction rule in Section 733. The section also preserves that payer coverage is governed by plan terms and does not create a separate mandate on insurers.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients seeking contraceptives — Easier, faster access to emergency, OTC, and certain prescription contraceptives without an immediate clinician visit, and the option to receive up to a 12‑month supply at once.
- Community and retail pharmacies — Expanded scope of services attracts more patients and creates new revenue and service‑line opportunities for pharmacists and pharmacy chains.
- Public health programs — Greater continuity of contraceptive coverage and fewer interruptions in use can reduce unintended pregnancies and associated public costs.
- Primary care access in underserved areas — Patients in clinician deserts may get timely contraceptives from nearby pharmacies, helping fill geographic gaps in clinician availability.
Who Bears the Cost
- Pharmacies and pharmacy employers — New operational costs: protocol development or implementation, staff training, inventory management for a broader product mix, documentation systems for PCP notification, and time for patient counseling and factsheet provision.
- Individual pharmacists — Additional professional responsibilities, training requirements, documentation duties, and potential liability exposure tied to furnishing decisions and reliance on self‑screened patient data.
- Payers and employers (indirectly) — Increased requests for 12‑month dispensing could shift up‑front drug costs to payers and affect pharmacy benefit manager processes, while employer accommodation duties for conscience refusals may require staffing adjustments.
- Licensing boards and regulators — The Board of Pharmacy and the Medical Board must invest staff time to draft protocols, coordinate stakeholder consultations, and enforce compliance across different licensee types.
Key Issues
The Core Tension
The central tension is between widening immediate access to contraception by empowering pharmacists and preserving coordinated, clinically safe contraceptive care: expanding pharmacist furnishing reduces access barriers but transfers assessment, documentation, and follow‑up responsibilities (and associated risks and costs) into pharmacy settings, forcing regulators and payers to choose how much structure and oversight are necessary without undoing the access gains the bill seeks to create.
The bill threads several competing objectives together — increasing access, protecting clinician conscience, and maintaining clinician oversight — but leaves unresolved questions about how those goals will be operationalized. The requirement that prescription‑only protocols be jointly approved by the Board of Pharmacy and the Medical Board ensures clinical input, but the statute does not specify timelines, minimum content beyond the USMEC‑based self‑screening requirement, or how localized protocols (the statute allows pharmacist‑prescriber protocols for emergency contraception) will interact with statewide protocols.
The law sets low‑bar training for one element (a single hour of continuing education for emergency contraception) while imposing broader documentation and notification duties that may create administrative burden. The removal of the prior prohibition on pharmacists charging a separate consultation fee (the bill deletes that earlier restriction) raises practical questions about billing transparency and out‑of‑pocket costs for patients; the statute also stops short of requiring insurers to cover a 12‑month supply, so coverage and patient cost‑sharing will remain uncertain.
Finally, enforcement is split between two licensing boards, which could produce inconsistent interpretations or patchwork enforcement unless the boards coordinate rulemaking and guidance early and explicitly.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.